| 0.126 -0.004 (-3.08%) | 12-29 14:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Oncorus, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering viral immunotherapies designed to combat cancer in patients. At the forefront of its pipeline is ONCR-177, an innovative viral immunotherapy that leverages a modified herpes simplex virus type 1 (oHSV-1) platform. This candidate, administered directly into tumors, is presently undergoing Phase I clinical evaluation for a range of different cancers. Beyond this, Oncorus is advancing ONCR-GBM, an oHSV program in preclinical development targeting brain cancer via intratumoral injection. Further research includes synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. In a significant collaboration, Oncorus has partnered with MSD International GmbH (Merck) through a clinical trial and supply agreement. This partnership aims to assess the safety and tolerability of ONCR-177 when administered in combination with Merck's well-known cancer immunotherapy, KEYTRUDA, during a Phase I clinical trial involving patients with solid tumors. Established in 2015, Oncorus, Inc. maintains its headquarters in Cambridge, Massachusetts.
Sat, 18 Apr 2026
Eric H Rubin Net Worth (2026) - GuruFocus
Tue, 26 Mar 2024
Oncorus (NASDAQ: ONCR) - Share Price - www.intelligentinvestor.com.au
Tue, 02 Jan 2024
The definitive Boston biotech layoff tracker for 2023 - The Business Journals
Mon, 12 Jun 2023
After layoffs leave Oncorus a 'shell' of a company, board liquidates the business - Fierce Biotech
Wed, 30 Nov 2022
Oncorus drops HSV solid tumor prospect, lays off 15% of workforce - Fierce Biotech
Thu, 23 Jun 2022
Oncorus Appoints Douglas Fambrough to Board of Directors - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|